Atlas Trials

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Clinical trial NCT05522231 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05522231
Sponsor
Hutchmed
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Advanced Renal Cell Carcinoma
Start date
2022-10-27
Primary completion
2025-01-01
Enrollment
265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.